🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06898489
Active, not recruiting Observational

Adjunctive Yu-Tone Music Therapy for Systemic Lupus Erythematosus: a Prospective Cohort Study

NCT06898489 · tracked via the Priya Life Science China tracker
Sponsor
Yijun Luo
Phase
Observational
Started
2025-03-01
Last updated
2025-03-27

Condition(s) studied

Systemic Lupus ErythematosusMusic Therapy

Investigational drug(s) / intervention(s)

Yu-Tone Music InterventionConventional pharmacotherapy

Yu-Tone Music Intervention: SLE patients undergo a structured Yu-tone music listening program (30 minutes daily, 5 days per week, with each cycle lasting 8 weeks, for a total of 3 cycles

Conventional pharmacotherapy: Standard SLE medications (e.g., hydroxychloroquine, glucocorticoids).

Study summary

The goal of this observational study is to investigate the long-term adjunctive effects of Traditional Chinese Five-Tone Therapy (Yu Tone) in patients with systemic lupus erythematosus (SLE). The main question it aims to answer is:

Does Yu-tone music therapy improve psychological well-being and quality of life in SLE patients when used as a complementary intervention alongside standard pharmacotherapy? Participants already receiving Yu-tone music therapy as part of their integrative care for SLE will complete validated online questionnaires assessing psychological distress (e.g., anxiety, depression), disease-related quality of life, and medication adherence monthly for 2 years.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * Meet the 2019 ACR/EULAR classification criteria for SLE; ② Adults aged 18 years or older; ③ Provide informed consent to participate in the study. Exclusion Criteria: * Presence of severe organ dysfunction (e.g., renal failure, cardiac insufficiency) or psychiatric disorders; ② Diagnosed with hearing impairment or auditory disorders; ③ Inability to comprehend or complete study questionnaires (e.g., due to cognitive impairment or language barriers).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hangzhou, 310053, China. Hangzhou China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06898489 on ClinicalTrials.gov ↗ ← All trials in China